INTRODUCTION
Cancer cachexia is a complex syndrome wherein severe, progressive, loss of body weight is mainly accounted for by wasting of host body compartments such as skeletal muscle and adipose tissue. Weight loss and tissue wasting are observed in up to twothirds of patients dying from cancer (Kern and Norton, 1988) , and weight loss implies poorer prognosis and shorter survival time for cancer patients (De Wys, 1985) . Moreover, the management of cachexia raises serious, largely unresolved, problems.
In dealing with clinical or experimental cancer cachexia, most approaches imply the assumption, even if not openly stated, that the underlying disturbances can be largely equated to a situation of malnutrition accounted for by factors such as hypophagia, malabsorption or metabolic competition by tumour cells. Total parenteral nutrition has thus been extensively evaluated as a supportive therapy to reverse cachexia (Brennan, 1981; Rumley and Copeland, 1985) , yet proved disappointing in tumourbearing animals (Cameron, 1981; Popp et al., 1981 Popp et al., , 1984 as well as in cancer patients (Chlebowski, 1985; Bozzetti et al., 1987; Shaw and Wolfe, 1988; Hyltander et al., 1991) . Moreover, although the inability to utilize food conveniently is accompanied by a devastating breakdown of the lean body mass (Lundholm et al., 1976) , a potential pitfall of total parenteral nutrition is that the tumour itself may benefit by the extra nutrients supplied (Cameron, 1981; Baron et al., 1986) .
As worked out in our laboratory, the rat ascites hepatoma Yoshida AH-130 has proved a very convenient model to study cancer cachexia. This develops early after tumour transplantpartial prevention of muscle waste was observed with acetylsalicylic acid, a non-steroidal anti-inflammatory drug, or with leupeptin, a proteinase inhibitor. Insulin afforded the most significant preservation of muscle protein and adipose-tissue mass, which were maintained close to control values even 10 days after transplantation. The effects of insulin on gastrocnemius muscle and liver protein content were exerted by slowing down protein turnover, mainly enhancing synthesis. Consistently, the total free amino acid concentration in the gastrocnemius of insulin-treated rats 10 days after tumour transplantation was close to that of controls. Although treatment with insulin decreased plasma corticosterone to normal values, it did not modify the circulating level of tumour necrosis factor. On the whole these data show that it seems possible to prevent, at least in part, the tissue waste that characterizes cancer cachexia by purely pharmacological means.
ation, in association with enhanced tissue protein catabolism (Tessitore et al., 1987 (Tessitore et al., , 1993a , adipose-tissue depletion (N. Carbo, P. Costelli, L. Tessitore, G. J. Bagby, F. J. Lopez-Soriano, F. M. Baccino and J. M. Argiles, unpublished work) and humoral perturbations all poised in a catabolic sense, such as decrease of plasma insulin (INS), elevation of counter-regulatory mediators [glucagon, corticosterone, catecholamines and prostaglandin E2 (PGE2)], and presence of circulating tumour necrosis factor (TNF), a putative catabolic cytokine (Tessitore et al., 1993b) . Data from another laboratory are consistent with such a general pattern (Strelkov et al., 1989; Baracos et al., 1992) . Neither the observed decrease in food intake (Tessitore et al., 1993a,b) nor the tumour-host competition (Tessitore et al., 1987 (Tessitore et al., , 1993a could by themselves account for the metabolic derangement and tissue wasting in tumour bearers. Rather, these changes appeared largely determined by a complex network of humoral factors that all forced tissue metabolism, particularly protein turnover, into a catabolic setting.
The possibility of interfering with the onset of the main metabolic disturbances in AH-130 tumour-bearing rats has been investigated in the present study. In view of our previous observations, the rationale was to scrutinize some treatments selected for their ability to (Tessitore et al., 1987 (Tessitore et al., , 1993a that cachexia in this model mostly results from a tissue hypercatabolic state developing in the course of the tumour-host interaction.
EXPERIMENTAL
The experiments were performed on male Wistar rats weighing about 200 g (Nossan, Milano, Italy), having unrestricted access to food and water, and maintained under a 12 h-light/ 12 h-dark cycle. The diet (Piccioni, Brescia, Italy) was constituted of 49 % carbohydrates, 200% protein and 50% fat; the rest was nondigestible material. Rats receiving an intraperitoneal inoculum of 5 x 107 Yoshida ascites-hepatoma AH-130 cells showed an appreciable body weight loss as early as 48 h after transplantation, and died in about 15 days (cf. Tessitore et al., 1987) . Both tumour-bearing and non-tumour-bearing rats were divided into two groups for each treatment (controls and treated). The daily food intake of tumour bearers was measured, and pair-fed controls were provided with the same amount of food.
INS and LPP were given since day 1 after transplantation by subcutaneous injections, the former daily (15 units/kg body wt.) and the latter 8-hourly (2.5 mg/kg body wt.) for a total of 4 (either drug) or 10 days (INS only). A priming dose of ASA (6 mg/kg body wt., subcutaneously) was followed by a daily maintenance dose (40 mg/kg body wt.) delivered for 4 or 7 days with an osmotic minipump (Alzet, Palo Alto, CA, U.S.A.) implanted subcutaneously in the back a few hours after tumour transplantation. MPA was injected daily (5 mg/rat, intramuscularly) for 10 days after the inoculum. Rats adrenalectomized 6 days before tumour transplantation were given 0.9 % (w/v) NaCl to drink and, to maintain their blood glucocorticoids within the normal range, a daily intramuscular injection of corticosterone (0.714 mg/kg body wt.) for the whole experimental period (from 6 days before transplantation until 4 or 10 afterwards).
Rats were weighed and anaesthesized with diethyl ether; tumours were harvested from the peritoneal cavity, their volume and cellularity were measured, and blood was collected from the abdominal aorta. Plasma was prepared by centrifuging the whole blood at 3000 rev./min for 15 min at 4°C and stored in batches at -80 'C. Many organs were removed and weighed, and liver and gastrocnemius muscle were frozen in liquid nitrogen and stored at -80 'C. The lumbar fat-pads were considered representative of the whole white-adipose-tissue mass; the brown adipose tissue was dissected from the interscapular white adipose tissue.
Protein turnover was evaluated as described by Tessitore et al. (1987 Tessitore et al. ( , 1993a . Animals received a single intraperitoneal dose of ['4C ]bicarbonate 1 day before tumour transplantation. Liver and gastrocnemius were homogenized to evaluate total and specific (per mg of protein) radioactivity, as previously reported (Baccino et al., 1982; Tessitore et al., 1987) . The following equations were used to calculate the fractional rates of protein synthesis (kQ), degradation (kd) and accumulation (ka): ks = ln (protein specific radioactivity)/t kd = ln (total protein radioactivity)/t ka = ln (total protein)/t a short discussion about the methodology as applied to liver and skeletal muscle.
Blood constituents, hormones, TNF and free amino acids in the gastrocnemius muscle were determined as previously reported (Tessitore et al., 1993a,b) .
Tissue proteinase activities were determined in the soluble extract of liver and gastrocnemius muscle obtained by centrifuging the crude homogenate (6 x 106 g-min at 4°C). Total activities of cathepsin B (EC 3.4.22.1), H (EC 3.4.22.16) and L (EC 3.4.22.15) were measured fluorimetrically by the methods described by Barrett (1980) and Barrett and Kirschke (1981) , by using synthetic substrates containing 4-methyl-7-coumarylamide (MCA). In particular, carboxybenzoyl-L-arginyl-L-arginyl-MCA, L-arginyl-MCA and carboxybenzoyl-L-phenylalanyl-Larginyl-MCA were the specific substrates for cathepsins B, H and L respectively. Cathepsin D (EC 3.4.23.5) activity was determined in the presence of 1 % (w/v) Triton X-100, by evaluating the hydrolysis of haemoglobin by the method of Barrett (1967) .
Data are presented as means+S.D. (or+S.E.M. in some Tables). Significance of differences was calculated by ANOVA. As for the fractional rates of protein turnover, comparisons were made on linear regressions (Lee and Lee, 1982) . 
RESULTS

Body weight, tissue weight and tissue protein
As previously reported (Tessitore et al., 1987) , the endoperitoneal growth of the AH-130 tumour was exponential for the first 5 days, then decelerated into a stationary state attained at approx. day 8. The present observations were generally made at two time points: day 4, as representative of the first phase, and day 7 or 10, corresponding to a beginning or fully established last phase. The daily food intake progressively decreased after tumour transplantation from 18 g (day 0) to about 10 g (day 10; cf. Tessitore et al., 1993a) . None of the treatments significantly affected this pattern, except INS, which augmented the food intake in tumour hosts to about 20 g at day 10 after implantation.
After tumour transplantation, rats suffered from a progressive severe loss of body weight and of skeletal-muscle protein, most notably from the gastrocnemius, until frank cachexia ensued (Tessitore et al., 1987 (Tessitore et al., , 1993a . The data for untreated tumour bearers in Figure 1 and in Tables 2-4 are consistent with those previously reported and further show that brown and, particularly, white adipose tissue were strongly depleted as well. Liver and spleen, after a transient increase in protein content, eventually shared the general pattern of wasting. Only adrenals were still enlarged at day 10.
Different treatments were evaluated on AH-130 tumourbearing animals. ASA is a cyclo-oxygenase inhibitor that, like indomethacin, has the ability to prevent the acceleration of muscle protein degradation induced by TNF (cf. Tanaka et al., 1989; Gelin et al., 1991) and PGE2 (cf. Gelin et al., 1991) , which are both elevated in AH-130 tumour hosts (Tessitore et al., 1993b ). Muscle wasting is frequently associated with increased activity ofproteolytic enzymes, and LPP is a well-known inhibitor
XReference is made to a previous paper (Tessitore et al., 1987) for of cysteine and other proteinases (cf. Tessitore et al., 1988) , which has been shown to prevent muscle waste in septic rats (Ruff and Secrist, 1984) . The analogue of megestrol acetate, MPA, has been reported to preserve the body weight in breastcancer patients (Tchekmedyian et al., 1987; Aisner et al., 1988 (Lynch et al., 1978; Gelin et al., 1991) , the lack of effects of INS is in keeping with the observation that protein turnover in AH-130 tumour cells is not altered by this hormone (Tessitore et al., 1988) .
Treatment with ASA had remarkable effects on tumour bearers at day 4. The loss of body weight (Figure 1 ) and of gastrocnemius wet weight ( produced a most severe depletion of white fat since day 4 (results not shown).
Blood plasma constituents
In AH-130 tumour hosts the development of cachexia was associated with pronounced alterations of blood plasma constituents; although glucose was normal (cf. Tessitore et al., 1993b) , total cholesterol and, even more, triacylglycerols were markedly increased (Dessi et al., 1992) . As shown in Table 5 (Table 6 ). The lack of effects of ASA on TNF levels may be consistent with its production by the tumour rather than by reactive cells (Tessitore et al., 1993b) .
Tissue protein turnover
To assess how the tissue protein changes in tumour hosts were modified by the above treatments, bulk protein turnover was evaluated in the liver and gastrocnemius by measuring protein radioactivity decay starting 24 h after labelling with NaH14CO3. As discussed previously (Tessitore et al., 1987) , this approach to investigate protein turnover in vivo is very suitable for the liver (Swick and Ip, 1974) , but it is affected by some degree of label recycling in skeletal muscle (MacDonald et al., 1979) . Two observation windows were adopted, corresponding to days 0-4 and days 4-10 after tumour transplantation. In liver, though not in muscle, protein turnover rates in these intervals were quite different, due to the heterogeneous half-lives of proteins of the slow-turnover pool (Garlick et al., 1975) ; thus comparisons among the experimental groups should only be made within the same interval. Previous data from our laboratory (Tessitore et al., 1987) have shown that the transient liver hyperplasia and the subsequent waste were associated with first decreased and then increased rates of protein degradation (kd), whereas synthesis rates (k.) were little affected (Table 7) . Gastrocnemius protein depletion resulted from enhanced breakdown, with no changes in synthesis rates (Table 8 ). In adrenalectomized tumour bearers the liver kd was augmented in the interval days 0-4 (Table 7) , whereas gastrocnemius protein turnover was not modified (Table 8) ; this is consistent with the abrogation ofthe transient liver hyperplasia, as well as with the lack of effects on muscle waste (Table 4 ). The enhancement of liver k. (Table 7) and that of muscle kd (Table 8) (Tables 2 and 4 ). Among the treatments tested, INS was again revealed as the most effective, increasing the ks in liver (Table 7) and muscle (Table 8) over both observation windows and decreasing the kd in muscle over days 0-4. The increase in gastrocnemius free amino acids at day 10 (Table 9) is consistent with the improved balance between protein synthesis 
Tissue proteinases
Since an increased activity of tissue proteinases such as cathepsin D (Lundholm et al., 1980; Greenbaum and Sutherland, 1983; Tessitore et al., 1993a ) has been suggested as a possible explanation for the accelerated tissue protein breakdown in tumourbearing animals, we examined the effects of the above treatments on various lysosomal proteinase activities. In the liver of AH-130 tumour bearers at day 4 the activities of cathepsins B, D, H and L were indeed significantly augmented on a tissue-protein basis (Figure 2 ), whereas both INS and ASA caused a significant decrease. A different pattern was observed after LPP, with only cathepsin H activity being decreased while that of cathepsins B, D, and L was further and sharply increased; this latter effect likely resulted from inhibition of intralysosomal enzyme breakdown. Only cathepsin D activity was found to be increased (by 55 %) in the muscle at day 4, and no activity was modified by any agent tested (results not shown). It is worth noting, however, that proteolytic pathways other than the lysosomal one may be involved in the enhancement of muscle protein breakdown in AH-130 tumour-bearers (Attaix et al., 1992; Baracos et al., 1992) .
DISCUSSION
In rats into which the ascites hepatoma Yoshida AH-130 was transplanted (Tessitore et al., 1987 (Tessitore et al., , 1993a , cachexia is characterized by early onset, rapid progressivity, and a general pattern of tissue waste that particularly involves skeletal muscle and adipose tissue. In previous work, the metabolic competition by the tumour (Tessitore et al., 1987 (Tessitore et al., , 1993a or the progressive decline in food intake (Tessitore et al., 1993a,b) did not appear to play a primary role in host wasting; rather, the dominant emerging feature was a hypercatabolic setting of tissue metabolism enforced through humoral mediation, and that should be viewed as cause rather than consequence of the waste (Tessitore et al., 1993b; Costelli et al., 1993 hormonal profile towards a catabolic pattern, increased plasma PGE2 and presence of circulating TNF, as detected in AH-130 tumour-bearing animals (Tessitore et al., 1993b) , could well account for such a mediation; but other factors such as yinterferon (Matthys et al., 1991) , leukaemia-inhibitory factor (Mori et al., 1991 ) or interleukin-6 (Greenberg et al., 1992 could play a role as well. It thus seemed of interest to examine whether pharmacological and hormonal interventions liable to interfere at various levels with the enhanced tissue protein degradation or other metabolic derangements could significantly prevent or attenuate tissue waste (Ruff and Secrist, 1984; Kettelhut et al., 1987; Moley et al., 1988) . Of interest, none of the present treatments significantly affected tumour growth or the circulating levels of TNF. In spite of the sustained elevation of plasma corticosterone and catecholamines in AH-130 tumour hosts (Tessitore et al., 1993b) , ADX did not substantially alter the general course of cachexia, in agreement with previous findings (Svaninger et al., 1987b) . By contrast, a partial but quite evident prevention of body-weight loss and muscle wasting was afforded by ASA at day 4 after tumour transplantation, though no longer at day 7; such effects may well be accounted for by the ability of this drug to interfere with the peripheral action of PGE2 or TNF, both of which are elevated in AH-130 tumour hosts (Tessitore et al., 1993b) . Likewise, muscle protein loss in AH-130 tumour hosts was partially prevented by the proteinase inhibitor LPP, probably via direct interference with the final proteolytic steps in protein degradation. LPP also abolished the elevation of plasma corticosterone in AH-130 bearers, while not affecting plasma INS. Although the effects of glucocorticoids on muscle protein turnover remain controversial (Odedra and Millward, 1984; Sugden and Fuller, 1991) , the present data do not rule out the possibility of an aggravating role for these hormones in tissue waste. Thus a possible indirect effect of LPP in this way cannot be ruled out.
Among the agents tested, INS proved the most effective on AH-130 tumour hosts at a daily dosage that was adequate to restore normal plasma INS levels (whereas corticosterone was not affected). Body weight, tissue protein content or turnover, adipose tissues and plasma lipids all showed marked and sustained improvements, likely reflecting the pleiotropic action of INS as well as the increased food intake (cf. Morrison, 1982; Moley et al., 1985 Moley et al., , 1988 Chance et al., 1986; Peacock et al., 1987; Rofe et al., 1989) . Tissue protein was preserved by INS through increased synthesis rates in the liver and gastrocnemius. Moreover, an appreciable decrease in breakdown rates was observed in the muscle, at least in the first observation window (days 0-4). Consistently, muscle total free amino acids were close to the control levels (cf. Chance et al., 1986) . These observations are in agreement with previous reports, wherein INS was shown to restore a positive nitrogen balance and to prevent the bodyweight loss in mice bearing the MAC 16 colon adenocarcinoma (Beck and Tisdale, 1989) or to preserve the body weight of sarcoma-bearing rats, though not prolonging their survival (Morrison, 1982; Moley et al., 1985 Moley et al., , 1988 ; moreover, wholebody protein turnover was improved by INS in cancer patients, however insulin-resistant they were with respect to glucose metabolism (Schein et al., 1979; Heslin et al., 1992) . Moreover, in spite of this marked anti-cachectic action, INS did not antagonize all of the metabolic perturbations in AH-130 hosts, such as, in particular, the elevation of plasma total cholesterol. This was suppressed by ASA, however, suggesting a role for some ASA-suppressible mechanism in the increase of total cholesterol. By contrast, elevation of triacylglycerols, though not affected by ASA, was suppressed by ADX or INS; since the latter agent also re-established a normal level of corticosterone, a role for this hormone in the increase in triacylglycerols can be postulated.
The present data further support the view (Tessitore et al., 1993b ) that the onset of cancer cachexia in AH-130 tumour hosts is related to the interplay of a complex network of factors that altogether concur in determining tissue waste by imposing a hypercatabolic state (cf. Lowry, 1991) . Treatment with anti-TNF antibodies (Costelli et al., 1993 Schein et al., 1979; Morrison, 1982; Chance et al., 1986; Peacock et al., 1987; Moley et al., 1988; Rofe et al., 1989) . In the present work, INS treatment restored a normal food intake in tumour bearers, which is likely to have concurred significantly in antagonizing the development of cancer cachexia. In view of the well-known observation that overfeeding is ofquite limited benefit to cancer patients (Brennan, 1981; Bozzetti et al., 1987; Shaw and Wolfe, 1988) , such an effect can hardly provide by itself a full explanation for the anticachectic action of INS. The data thus far available do not permit us to discriminate the respective contribution of these two mechanisms in the anti-cachectic action of INS on AH-1 30 hosts. Generally speaking, however, our previous and current observations on the present cachexia model lead us to share the view expressed by Heslin et al. (1992) , on the basis of clinical studies, that hormonal manipulations using anabolic agents such as INS may be expected to play a significant role in the management of cancer individuals. Further studies thus seem warranted in the search for drugs having the ability to interfere proximally or distally with the humoral mediation of cachexia. Along these lines, a note of caution is necessary, however, since such agents might also have the potential to accelerate tumour growth, either promoting cell proliferation or preventing cell death. This work was supported by the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (60% and 40% funds), Roma, the Consiglio Nazionale delle Ricerche (Special Project A.C.R.O.), Roma, and the Associazione Italiana per la Ricerca sul Cancro, Milano. P.C. received a fellowship from the Fondazione A. Bossolasco, Torino, Italy. Part of this work has been presented in a preliminary form at the European Congress on Geriatric Treatment: The Elderly at Risk, 1990 (Costelli et al., 1991 .
